CCM
SLDB icon

Camber Capital Management’s Solid Biosciences SLDB Stock Holding History

Camber Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,418,439
Closed -$8.71M – 43
2023
Q4 		$8.71M Hold
1,418,439
– – 0.22% 35
2023
Q3 		$3.57M Hold
1,418,439
– – 0.12% 39
2023
Q2 		$7.43M Hold
1,418,439
– – 0.24% 36
2023
Q1 		$6.72M Hold
1,418,439
– – 0.21% 39
2022
Q4 		$7.63M Buy
+1,418,439
New +$9.3M 0.26% 36

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Camber Capital Management's SLDB Position: Q1 2024 in Review

Camber Capital Management sold out of Solid Biosciences (SLDB) in Q1 2024, closing a stake of 1,418,439 shares — an estimated $8.71M sold.

Camber Capital Management first reported a position in SLDB in Q4 2022 and held it in 5 quarters. The position peaked at $8.71M in Q4 2023. 55 funds tracked by Wall St. Rank hold SLDB as of Q1 2024.

  • Camber Capital Management reported no remaining Solid Biosciences position as of Q1 2024 after selling out during the quarter.
  • Camber Capital Management sold 1,418,439 Solid Biosciences shares in Q1 2024, an estimated $8.71M.
  • Camber Capital Management first reported a position in Solid Biosciences in Q4 2022 and held it in 5 quarters.
  • Camber Capital Management's Solid Biosciences position peaked at $8.71M in Q4 2023.
  • 55 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2024.

Based on Camber Capital Management's 13F filing for Q1 2024, filed 15 May 2024.